01:18 PM EDT, 08/06/2025 (MT Newswires) -- Arch Biopartners ( ACHFF ) on Wednesday said it successfully dosed the first patient for its LSALT Peptide Phase II trial..

The dosing of the volunteer patient took place over five days as part of the company's Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery acute kidney injury (CS-AKI).

The company said it is pursuing additional clinical sites to conduct further testing.

"The goal is to recruit about half of the trial's patients in North America. Patient dosing completed in Turkey has provided a strong safety profile for LSALT peptide. This has given clinical trial teams increased confidence as new sites join the trial to test LSALT peptide's ability to protect kidneys from acute inflammation injury," chief executive Richard Muruve said.

Arch Biopartners ( ACHFF ) shares were last seen down $0.07 to $1.67 on the TSX Venture Exchange.

Price: 1.67, Change: -0.07, Percent Change: -4.02